Pervasis Therapeutics, Inc.: Series B $9.75M

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

ProtAffin Biotechnologie, AG: Series B €4.0M

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

Aushon Biosystems, Inc.: Series B $7.0M

Aushon Biosystems (Burlington, MA) provides advanced microarray technologies to life science research, drug discovery, development and clinical diagnostics closed on a $4M traunche $7M Series B. Participant was North Bridge Venture Partners.

Nitec Pharma AG.: Series B $26M

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.

Amira Pharmaceuticals, Inc.: Series B $25M

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNFα pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

ProteoGenix, Inc.: Series B $20M

ProteoGenix (Portland, OR) a diagnostics company utilizing high-throughput protein analysis techniques to identify protein biomarkers for pregnancy-related complications closed a $20M Series B round. The financing was led by New Leaf Venture Partners, TPG Growth and Burrill and Company.

Spaltudaq Corporation: Series B $29M

Spaltudaq (Seattle, WA) is focused on developing tumor-specific therapeutic antibodies for the treatment of cancer and infectious disease raised $29M in a Series B financing. The round was led by Arch Venture Partners and was joined by Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital and Alexandria Equities.

PainCeptor Pharma Corp: Series B $20.8M

PainCeptor (Canada) a drug company focused on the treatment of chronic and acute pain raised a $20.8M Series B round. The deal was lead by Desjardins Venture Capital, CDP Capital, T2C2 Capital, Business Development Bank of Canada and Lothian Partners.

Intarcia Therapeutics, Inc.: Series B $50M

Intarcia Therapeutics (Emeryville, CA) a biopharmaceutical company developing therapies for Type 2 Diabetes and Hepatitis C raised $50M in a Series BB Financing. The round was led by New Leaf Venture, and joined by Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, and Granite Global Ventures.

PneumRx, Inc.: Series B $27M

PneumRx (Mountain View, CA) a medical device company providing steerable biopsy needle devices to enhance lesion targeting and sampling, raised $27M Series B funding. The round was led by Adams Street Partners and Telegraph Hill Partners additional participants included Sage Venture Partners, Alta Partners, KBL Healthcare Ventures and Spray Venture Partners.